Guest
Pain is a major clinical, social and economic problem, affecting quality of life for hundreds of millions of people globally. Galit Zuckerman-Stark founded Medasense () to develop a technology that can transform the way pain is being assessed and treated worldwide. With a breakthrough AI technology and advanced sensing platform, Medasense’s flagship product, PMD-200™, is used in critical care settings, where patients are unable to communicate, to visualize pain response and personalize treatment. Clinical studies have demonstrated its impact on patient safety and outcomes – including opioid sparing and lower pain scores reported by patients. On our path to improving pain care in additional settings, we are harnessing our AI capabilities to lead prediction, stratification and prevention strategies to enable better pain management and reduce healthcare costs.
